1.Tenover, FC, Biddle, JW, Lancaster, MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327–332.
2.Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995;23:87–94.
3.Drinkovic, D, Taylor, SL, Pottumarthy, S, Morris, AJ. Prospective vancomycin audit in Auckland healthcare hospitals. N Z Med J 1999;112:336–339.
4.You, JH, Lyon, DJ, Lee, BS, Kwan, SM, Tang, HY. Vancomycin utilization at a teaching hospital in Hong Kong. Am J Health Syst Pharm 2001;58:2167–2169.
5.Beidas, S, Khamesian, M. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol 1996;17:773–774.
6.Watanakunakorn, C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767–769.
7.Cieslak, PR, Strausbaugh, LJ, Fleming, DW, Ling, JM. Vancomycin in Oregon: whO's using it and why. Infect Control Hosp Epidemiol 1999;20:557–560.
8.Green, K, Schulman, G, Haas, DW, Schaffner, W, D'Agata, EM. Vancomycin prescribing practices in hospitalized chronic hemodialysis patients. Am J Kidney Dis 2000;35:64–68.
9.Johnson, SV, Hoey, LL, Vance-Bryan, K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995;15:579–585.
10.Roghmann, MC, Perdue, BE, Polish, L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hosp Epidemiol 1999;20:60–63.
11.Singer, MV, Haft, R, Bariam, T, Aronson, M, Shafer, A, Sands, KE. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248–253.
12.Evans, ME, Kortas, KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol 1996;17:356–359.
13.Shah, SS, Sinkowitz-Cochran, RL, Keyserling, HL, Jarvis, WR. Vancomycin use in pediatric neurosurgery patients. Am J Infect Control 1999;27:482–487.
14.Kahyaoglu, O, Akpinar, M, Nolan, B, Inoue, S, Zureikat, G, Kumar, A. Vancomycin use and monitoring in pediatric patients in a community hospital. Infect Control Hosp Epidemiol 1998;19:299, 301.
15.Hopkins, HA, Sinkowitz-Cochran, RL, Rudin, BA, Keyserling, HL, Jarvis, WR. Vancomycin use in pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 2000;21:48–50.
16.Logsdon, BA, Lee, KR, Luedtke, G, Barrett, FF. Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria. Infect Control Hosp Epidemiol 1997;18:780–782.
17.Ena, J, Dick, RW, Jones, RN, Wenzel, RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993;269:598–602.
18.Nourse, C, Byrne, C, Leonard, L, Butler, KGlycopeptide prescribing in a tertiary referral paediatric hospital and applicability of Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines to children. Eur J Pediatr 2000;159:193–197.
19.Salemi, C, Becker, L, Morrissey, R, Warmington, J. A clinical decision process model for evaluating vancomycin use with modified HICPAC -guidelines;. Hospital Infection Control Practice Advisery Committee. Clin Perform Qual Health Care 1998;6:12–16.
20.Feldman, HA. Families of lines: random effects in linear regression analysis. J Appi Physiol 1988;64:1721–1732.
21.Diggle, P, Liang, K-Y, Zeger, SL. Analysis of Longitudinal Data: Oxford Statistical Science Series. Oxford: Oxford University Press; 1994:xi, 253.
22.Durmaz, G, Us, T, Aydinli, A, Kiremitci, A, Kiraz, N, Akgun, Y. Optimum detection times for bacteria and yeast species with the BACTEC 9120 aerobic blood culture system: evaluation for a 5-year period in a Turkish university hospital. J Clin Microbiol 2003;41:819–821.
23.Nucci, M, Landau, M, Silveira, F, Spector, N, Pulcheri, W. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 2001;22:651–653.
24.Paganini, H, Staffolani, V, Zubizarreta, P, Casimir, L, Lopardo, H, Luppino, V. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer 2003;39:1284–1289.
25.Kesler, RW, Guhlow, LJ, Saulsbury, FT. Prophylactic antibiotics in pediatric surgery. Pediatrics 1982;69:1–3.
26.Kwan, T, Lin, F, Ngai, B, Loeb, M. Vancomycin use in 2 Ontario tertiary care hospitals: a survey. Clin Invest Med 1999;22:256–264.